Table 1 Haematocrit, plasma sodium, potassium and lithium concentration candesartan treated rats.

Candesartan (mg kg^{-1} + µg min^{-1} kg^{-1})	Experimental period	Hct (%)	P_{Na} (mmol l^{-1})	P_K (mmol l^{-1})	P_{Li} (mmol l^{-1})
0.0+0.0	Control	43.7 ± 0.5	142.0 ± 0.2	3.7 ± 0.6	0.4 ± 0.01
(n=6)	Treatment	42.4 ± 0.3	143.2 ± 0.6	3.7 ± 0.1	0.4 ± 0.01
	Post treatment	42.3 ± 0.5	142.8 ± 0.6	3.6 ± 0.0	0.3 ± 0.01
0.01+0.5	Control	43.7 ± 0.5	136.6 ± 1.6	3.3 ± 0.1	0.4 ± 0.02
(n=8)	Treatment	42.4 ± 0.3	140.5 ± 1.1	3.4 ± 0.1	0.4 ± 0.02
	Post treatment	42.3 ± 0.5	140.2 ± 1.0	3.2 ± 0.1	0.4 ± 0.02
0.1+5	Control	46.6 ± 0.7	142.1 ± 1.0	3.5 ± 0.1	0.2 ± 0.02
(n=7)	Treatment	46.6 ± 0.8	141.1 ± 0.8	3.4 ± 0.1	0.2 ± 0.02
	Post treatment	45.9 ± 1.0	142.2 ± 1.4	3.5 ± 0.1	0.2 ± 0.02
0.2+10	Control	43.7 ± 1.4	137.4 ± 1.0	3.5 ± 0.1	0.3 ± 0.01
(n=5)	Treatment	43.4 ± 1.0	138.3 ± 1.6	3.5 ± 0.1	0.3 ± 0.01
	Post treatment	41.8 ± 1.3	137.7 ± 1.6	3.4 ± 0.1	0.3 ± 0.01
0.5+25	Control	45.4 ± 1.0	145.7 ± 4.8	3.6 ± 0.1	0.1 ± 0.10
(n=5)	Treatment	44.7 ± 0.8	146.6 ± 5.2	3.6 ± 0.0	0.1 ± 0.10
	Post treatment	44.2 ± 0.6	144.0 ± 1.6	3.4 ± 0.1	0.1 ± 0.10
1.0+50	Control	45.5 ± 1.4	140.8 ± 0.8	3.5 ± 0.1	0.1 ± 0.10
(n=5)	Treatment	45.0 ± 1.2	140.9 ± 0.8	3.5 ± 0.1	0.2 ± 0.10
	Post treatment	45.1 ± 1.2	144.6 ± 0.8	3.5 ± 0.1	0.1 ± 0.10

Figure labels

Figure 1 Mean arterial blood pressure (MABP), and urine flow in non-treated (0+0) and candesartan-treated rats. Each point is mean ± SE of three 60 min experimental periods (control, candesartan and recovery). Candesartan was given as a bolus dose in mg kg^{-1} following by constant infusion at μg kg^{-1} min^{-1}. Parenthesis indicates number of animals. Significant differences within group are represented by * (P<0.05). The figure legend corresponds to all graphs. kw = kidney weight.

Figure 2 Renal haemodynamic responses in non-treated (0+0) and candesartan-treated rats. Each point is mean ± SE of 60 min experimental periods (control, candesartan and recovery). Candesartan was given as a bolus dose in mg kg^{-1} following by constant infusion at μg kg^{-1} min^{-1}. Parenthesis indicates number of animals. Significant differences within group are represented by * (P<0.05). The figure legend corresponds to all graphs. GFR = glomerular filtration rate, RPF = renal plasma flow, FF = filtration fraction and kw = kidney weight.

Figure 3 Effects of candesartan on urinary excretion of sodium and potassium. Each point is mean ± SE of 60 min experimental periods (control, candesartan and recovery). Candesartan was given as a bolus dose in mg kg^{-1} following by constant infusion at μg kg^{-1} min^{-1}. Parenthesis indicates number of animals. Significant differences within group are represented by * (P<0.05). The figure legend corresponds to all graphs. $U_{Na}V$ = sodium excretion rate, FE_{Na} = fractional excretion of sodium, U_KV = potassium excretion rate, FE_K = fractional excretion of potassium, and kw = kidney weight.

Figure 4 Effects of candesartan on lithium excretion and proximal reabsorption of sodium. Each point is mean ± SE of 60 min experimental periods (control, candesartan and recovery). Candesartan was given as a bolus dose in mg kg^{-1} following by constant infusion at μg kg^{-1} min^{-1}. Parenthesis indicates number of animals. Significant differences within group are represented by * (P<0.05). The figure legend corresponds to all graphs. CLi = lithium clearance, FE_{Li} = fractional excretion of lithium, FPR_{Na} = fractional proximal reabsorption of sodium and kw = kidney weight.


control
candesartan
post treatment
MABP (mmHg)
160
140
120
100
80
60
40
20
0
(6)
(8)
(7)
(5)
(5)
(5)
0+0
0.01+0.5
0.1+5
0.2+10
0.5+25
1.0+50
Urine flow (µl min-1 g kw-1)
50
40
30
20
10
0
0+0
0.01+0.5
0.1+5
0.2+10
0.5+25
1.0+50
Candesartan (mg kg-1 + µg kg-1min-1)


control
candesartan
post treatment
GFR (ml min-1g kw-1)
2.0
1.6
1.2
.8
.4
0.0
(6)
(8)
(7)
(5)
(5)
(5)
RPF (ml min-1g kw-1)
6
5
4
3
2
1
0
Filtration Fraction (%)
60
50
40
30
20
10
0
0+0
0.01+0.5
0.1+5
0.2+10
0.5+25
1.0+50
Candesartan (mg kg-1 + µg kg-1min-1)


control
candesartan
post treatment
(6)
(8)
(7)
(5)
(5)
(5)
$U_{Na}V$ (µmol min^{-1}g kw^{-1})
FE_{Na} (%)
U_KV (µmol min^{-1}g kw^{-1})
FE_K (%)
0+0
0.01+0.5
0.1+5
0.2+10
0.5+25
1.0+50
Candesartan (mg kg^{-1} + µg kg^{-1}min^{-1})


control
candesartan
post treatment
(6)
(8)
(7)
(5)
(5)
(5)
C_{Li} (ml min^{-1}g kw^{-1})
1.0
.8
.6
.4
.2
0.0
FE_{Li} (%)
60
50
40
30
20
10
0
FPR_{Na} (%)
80
70
60
50
40
30
20
10
0
0+0
0.01+0.5
0.1+5
0.2+10
0.5+25
1.0+50
Candesartan (mg kg^{-1} + µg kg^{-1}min^{-1})